Halozyme Therapeutics | HALO - Loan Capital


Halozyme Therapeutics reported $1.94B in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
Amgen USD 51.86B 27M Jun/2026
Baxter International USD 8.62B 6M Jun/2026
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 248.2M 993K Jun/2026
DBV Technologies USD 0 0 Mar/2025
Eli Lilly USD 47.86B 8.49B Jun/2026
Halozyme Therapeutics USD 1.94B 1.79M Jun/2026
Intrexon USD 0 198.67M Jun/2024
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
MannKind USD 545.13M 2.93M Jun/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Pfizer USD 60.5B 70M Jun/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024